Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty

Publication Date: June 20, 2022
Last Updated: June 21, 2022

Summary of Recommendations (all are conditional)

Continue the current dose of methotrexate, leflunomide, hydroxychloroquine, and/or sulfasalazine (nonbiologic DMARDs) for patients undergoing elective THA or TKA. (Level of Evidence: Low - Moderate) ( Conditional , Moderate )
SLEa
RA, SpA including
AS and PsA
JIA Nonbiologic
DMARDs
SLE Severe SLE
607

Overview

Title

Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty

Authoring Organizations